Skip to main content
. 2023 Nov 21;17:1634. doi: 10.3332/ecancer.2023.1634

Table 2. Baseline characteristics.

Patient characteristics n: 51 p %
Female
Male		 50
1		 98.0
2.0
Mean age (years) 47.08 23–83
Premenopausal 26 52.0
Meta or synchronic bilateral BCa 4 8.0
BC subtype n: 51 p %
ER+/HER2-
TN
ER+/HER2+		 32
18
1		 62.7
35.3
2.0
Disease-free intervalb n: 47 p %
De novo stage IV or ≤12-months
Relapse >12-months		 17
30		 36.2
63.8
sPIK3-CA statusc n: 26 p %
Wild-type
Mutated		 19
7		 73.1
26.9
Previous treatment n: 51 p %
Neoadjuvant and/or adjuvant CT
Anthracyclines
Taxanes
Anthracyclines + taxanes
CT + platinum-based
CT + capecitabine
Others		 30
3
2
15
4
2
4		 75.0
10.0
6.7
50.0
13.3
6.7
13.3
Adjuvant endocrine therapy n: 19 p %
Tamoxifen
Aromatase inhibitors		 14
5		 73.7
26.3
Advanced CT lines n: 50 p %
0 lines
1 line
2 lines
3 lines
Median lines of ABC CT		 28
16
4
2
0		 56.0
32.0
8.0
4.0
0–3
Advanced endocrine therapy lines n: 35 p %
0 lines
1 line
2 lines
3 lines
Median Lines of ABC ET		 6
17
11
1
1		 17.1
48.6
31.4
2.9
0–3
ET + CDK4/6 inhibitors 28 82.4
ET + mTOR inhibitors 7 20.6
Alpelisib 2 6.1
Fulvestrant 15 44.1
ICP inhibitors 1 5.0
Number of lines before PARP inhibitors
0 lines
1 line
2 lines
3 lines
≥4 lines
Median lines before PARPi		 12
16
15
2
6
2		 23.5
31.4
29.4
3.9
11.8
0–8
PARP inhibitor indicated
Talazoparib
Olaparib		 32
19		 62.7
37.3
PbCT in (neo)adjuvant or advance setting 18 37.5
PbCT in the advance setting pre-PARPi 13 25.5
PARP inhibitors before or after CT in ABC
PARP inhibitors before CT
PARP inhibitors after CT		 25
22		 53.2
46.8
Platinum-free interval
≤6 months
>6 to 12 months
>12 months		 9
5
4		 50.0
27.8
22.2
Metastatic sites
Bone
Visceral
More than two
Soft tissue
CNS w/wo others		 7
27
8
5
1		 14.9
57.4
17.0
10.6
6.7
Number of metastatic sites
1
2
3
4
Median number of metastatic sites		 17
19
14
1
2		 33.3
37.3
27.5
2.0
1–4
ECOG performance status
0
1
≥2		 31
18
2		 60.8
35.3
4.0
Concomitant RT with PARP inhibitors 9 17.6
a

3 p with billateral BC with different phenotypes

b

6 p unknown

c

3 p unknown

ICP, immune-check points inhibitors. CT, chemotherapy. ET, endocrine therapy. ABC, advanced breast cancer. RT, radiation therapy